Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Completed
- Conditions
- Osteoporosis, Age-Related
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 935
- Registration Number
- NCT02732210
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
Phase 3
Completed
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 129
- Registration Number
- NCT02729025
- Locations
- 🇳🇱
Research Site, Waalwijk, Netherlands
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 142
- Registration Number
- NCT02675452
- Locations
- 🇨🇦
University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇩🇪Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
Phase 3
Completed
- Conditions
- Diabetes, Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 986
- Registration Number
- NCT02662569
- Locations
- 🇹🇷
Research Site, Kocaeli, Turkey
Observational Study of Apremilast in Patients With Psoriasis in The Netherlands
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 154
- Registration Number
- NCT02652494
- Locations
- 🇳🇱
Antonius Ziekenhuis Sneek, Sneek, Friesland, Netherlands
🇳🇱Bravis Ziekenhuis, Bergen op Zoom, North-Brabant, Netherlands
🇳🇱Amphia, Breda, North-Brabant, Netherlands
Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT02641353
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease
Phase 2
Completed
- Conditions
- In-situ Small Bowel T-cell LymphomaType II Refractory Celiac Disease (RCD-II)
- Interventions
- Biological: PlaceboBiological: AMG 714
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT02633020
- Locations
- 🇪🇸
Clinical Site, Madrid, Spain
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 475
- Registration Number
- NCT02630459
- Locations
- 🇯🇵
Research Site, Kai-shi, Yamanashi, Japan
A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT02626793
- Locations
- 🇩🇪
Gertraud Krähn-Senftleben, Blaubeuren, Baden-Württemberg, Germany
🇩🇪Clarissa Allmacher, Hersbruck, Bayern, Germany
🇩🇪Ildiko Sugar-Bunk, Krumbach, Bayern, Germany
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
Phase 1
Completed
- Conditions
- Carcinoma of the Head and Neck
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT02626000
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath